A must-read review on non-clear cell RCC! @JCOOP_ASCO 👉 https://t.co/Ai1clNBHdT @ASCO #Cancer #Oncology @OncoAlert @PBarataMD

Top GU Cancer Oncologists from @myESMO 2025 Explore more insights and data from #ESMO25: https://t.co/6VyXEIDUr8 #LARVOL #CancerResearch #CancerData #Oncology #OncologyInsights #ClinicalTrials #MedicalOncology #ESMO2025 #GUCancer | @DrChoueiri | @MikeSerzanMD | @nataliagandur |

Dear Colleagues at #ESMO25 Honored to present our OncoAlert Faculty🚨 @tompowles1 🇬🇧 who presented IMvigor011 in Berlin with a Concomitant Publication on the @NEJM showing ctDNA🧬 is a useful predictive and prognostic tool post cystectomy in muscle invasive #BladderCancer

After ESMO, hope feels stronger. Smarter and more effective treatments are coming for our patients. But science becomes a revolution only when it reaches people. May they not have to wait too long. Every oncologist is, above all, an advocate, our job is to bring treatments from

Which combination would you prefer for the first-line treatment in a patient with HER2-positive metastatic bladder cancer? #ESMO25 #bladdercancer @DrYukselUrun @OncBrothers @OncoAlert @tompowles1 @yekeduz_emre @dr_yakupergun

Grateful to have presented our work on the cytokine landscape of exceptional responders to IO-based combinations in mRCC at #ESMO25 and to have received the Merit Award that made this trip possible Congrats to the scientific chairs @DrChoueiri @MyriamChalabi for an excellent

Great memories from #ESMO25! It was a pleasure to discuss with amazing mentors Dr. @Ioanna_Nixon , MPH, PhD, FFMLM, FRCR(hon) and Dr. @DrVilmaPBarcia MD, PhD, MSc . 🌿

Wonderful poster by @Mustafajsalehmd on germline predictors of immunotherapy response on day 4 of #ESMO25! @DrChoueiri @SashaGusevPosts

Lu-PSMA combined with ADT+ARPI improved rPFS against ADT+ARPI in pts with mHSPC! OS was immature! #ESMO25 @myESMO @DrYukselUrun @DrChoueiri @OncoAlert @OncLive

Ivonescimab + chemo improved PFS over tislelizumab + chemo (11.1 vs 6.9 mo, HR 0.60, p<0.0001) in 1L sq-NSCLC. Benefit seen across PD-L1 groups. Dual target strategy keeps moving, VEGF still matters. #ESMO25 @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle

Practice-informing but not pivotal by @DrPaulNguyen: ENZARAD Ph III: ADT+RT ± enzalutamide for high-risk localized PCa. MFS HR 0.88 (95% CI 0.67-1.15); p=0.34. PSA PFS 0.78 (0.61, 0.99), p=0.044. #ESMO25 #ProstateCancer @myESMO @Annals_Oncology @OncLive @OncoAlert @DanaFarber

In contrast to abiraterone, adding enzalutamide to ADT with RT in pts with high-risk localized prostate cancer did not improve survival outcomes! ENZARAD trial #ESMO25 @myESMO @DrYukselUrun @DrChoueiri @Silke_Gillessen @APCCC_Lugano @OncoAlert @dmukherji @neerajaiims

Super star @MarcMachaalani from @DanaFarber_GU @harvardmed presented MADcAM-1 as a potential biomarker in mRCC! #ESMO25 @myESMO @DrChoueiri @DrYukselUrun @OncoAlert @OncLive

At #ESMO25 in Berlin. Eloquently discussed: biomarkers in renal cell carcinoma—LAG3, KIM-1, TILs. @SScagliarini_ @myESMO @OncoAlert @ONCOassist

Influential high-impact biomarker presentation by @DrRanaMcKay with LAG3 expression: LAG3-high tumors show inflamed RNA expression (↑PD-L1/CTLA4/TIGIT) and better early IO response; low LAG3 → reduced real-world ORR & more PD across 1L IO. #ESMO25 #RCC @myESMO @Annals_Oncology

Dr. Berkay Simsek from @BrighamWomens @harvardmed gave a great talk on the role of biomarkers of tumor microenvironment in mRCC! #ESMO25 @myESMO @DrYukselUrun @DrChoueiri @OncoAlert @DanaFarber_GU #cancer #Oncology

At #ESMO25, data on LAG-3 in RCC shows how the immune system can be both the soldier and the brake. @DrRanaMcKay @TeresaSAmaral @E_de_Azambuja @JyotiBajpai01 @ArBayle @Ecastromarcos @GillSharlene @PGrivasMDPhD @ErikaHamilton9 @DrAngelaLamarca @DrJonLim @StephenVLiu

What is the role LAG-3 in mRCC? RNAseq analysis is being presented by @DrRanaMcKay #ESMO25 @DrYukselUrun @DrChoueiri @myESMO @OncoAlert

EV+Pembro set the bar again in UC! This is the new standard in the neoadjuvant setting among cisplatin-ineligible patients! #ESMO25 @DrYukselUrun @myESMO @OncoAlert @OncLive #Cancer #Oncology